Ten Eyck L, MacLeod S, Hawkins K, Guimont R, Hartley S. The impact of a heart failure management program in a medicare advantage population. Popul Health Manag. 2019 Apr;22(2):153-61. doi: 10.1089/pop.2018.0072
Bennett KJ, Probst JC, Bullard JC, Crouch E. The importance of rural hospitals: transfers and 30-day readmissions among rural residents and patients presenting at rural hospitals. Popul Health Manag. 2019 Apr;22(2):120-6. doi: 10.1089/pop.2018.0050
MacLeod S, Schwebke K, Hawkins K, Ruiz J, Hoo E, Yeh CS. Need for comprehensive health care quality measures for older adults. Popul Health Manag. 2018 Aug;21(4):296-302. doi: 10.1089/pop.2017.0109
Rajan SS, Suryavanshi MS, Karanth S, Lairson DR. The immediate impact of the 2009 USPSTF screening guideline change on physician recommendation of a screening mammogram: findings from a national ambulatory and medical care survey-based study. Popul Health Manag. 2017 Apr;20(2):155-64. doi: 10.1089/pop.2015.0180.
Mehta H, Patel J, Parikh RC, Abughosh S. Differences in obesity management among physicians. Popul Health Manag. 2012 Oct;15(5):287-92.
Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.
Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.
Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.